Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Fa Yi Xue Za Zhi ; 26(1): 30-2, 2010 Feb.
Article in Chinese | MEDLINE | ID: mdl-20232740

ABSTRACT

OBJECTIVE: To study the relation between human blood estazolam concentration and neurobehavioral function. METHODS: The neurobehavioral ability of 10 volunteers were measured with computer-administered neurobehavioral evaluation system-chinese3 (NES-C3) and SMART EquiTest system. RESULTS: The neurobehavioral ability and balance function declined 1 h later after dosing estazolam. The neurobehavioral ability index and balance function declined to the lowest level 3 h later after dosing estazolam. The neurobehavioral ability recovered partly 6 h later after dosing estazolam, and neurobehavioral ability recovered completely 10 h later. CONCLUSION: Driving ability was impaired when estazolam concentration in blood is 20 ng/mL, and the neurobehavioral ability declined when estazolam concentration is 40 ng/mL in blood. The influence to human in absorption process is greater than the metabolic process with the same estazolam concentration.


Subject(s)
Accidents, Traffic/prevention & control , Attention/drug effects , Behavior/drug effects , Estazolam/adverse effects , Estazolam/pharmacokinetics , Psychomotor Performance/drug effects , Administration, Oral , Adult , Anticonvulsants/adverse effects , Anticonvulsants/blood , Anticonvulsants/pharmacokinetics , Estazolam/blood , Female , Humans , Male , Neuropsychological Tests , Reaction Time
2.
Journal of Forensic Medicine ; (6): 30-32, 2010.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-983534

ABSTRACT

OBJECTIVE@#To study the relation between human blood estazolam concentration and neurobehavioral function.@*METHODS@#The neurobehavioral ability of 10 volunteers were measured with computer-administered neurobehavioral evaluation system-chinese3 (NES-C3) and SMART EquiTest system.@*RESULTS@#The neurobehavioral ability and balance function declined 1 h later after dosing estazolam. The neurobehavioral ability index and balance function declined to the lowest level 3 h later after dosing estazolam. The neurobehavioral ability recovered partly 6 h later after dosing estazolam, and neurobehavioral ability recovered completely 10 h later.@*CONCLUSION@#Driving ability was impaired when estazolam concentration in blood is 20 ng/mL, and the neurobehavioral ability declined when estazolam concentration is 40 ng/mL in blood. The influence to human in absorption process is greater than the metabolic process with the same estazolam concentration.


Subject(s)
Adult , Female , Humans , Male , Accidents, Traffic/prevention & control , Administration, Oral , Anticonvulsants/pharmacokinetics , Attention/drug effects , Behavior/drug effects , Estazolam/pharmacokinetics , Neuropsychological Tests , Psychomotor Performance/drug effects , Reaction Time
3.
Arzneimittelforschung ; 58(10): 501-4, 2008.
Article in English | MEDLINE | ID: mdl-19025059

ABSTRACT

AIM: To compare the bioavailability of two estazolam (CAS 29975-16-4) tablet formulations (Estalin 2 mg tablets as test formulation and 2 mg tablets of the originator product as reference formulation). METHODS: The study was conducted according to an open label, randomized two-way cross-over design with a two-week washout period. Twenty-four subjects received each of the two estazolam formulations. Blood samples for pharmacokinetic profiling were taken up to 72 h after drug administration in fasting condition. Plasma concentrations of estazolam were determined with a validated HPLC method with ultraviolet detection. Pharmacokinetic parameters were calculated from observed plasma concentration-time profiles. RESULTS: The mean AUC(0-t), AUC(0-infinity) and Cmax were 2581.38 ng x h/mL, 2934.37 ng x h/mL and 95.25 ng/mL, respectively for the test formulation and 2835.75 ng x h/ mL, 3207.73 ng x h/mL and 99.32 ng/mL, respectively, for the reference formulation. The median Tmax for both formulations was 1 h. The point estimates and 90% confidence Intervals for AUC(0-t), AUC(0-infinity) and Cmax were 91.03% (87.48-94.72%), 91.48% (86.67-96.55%) and 95.90% (92.60-99.31%) respectively, satisfying the bloequivalence criteria of the European Committee for Proprietary Medicinal Products and the US Food and Drug Administration guidelines. CONCLUSION: These results indicate that two formulations of estazolam are bioequivalent and, thus, may be prescribed interchangeably.


Subject(s)
Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/pharmacokinetics , Estazolam/administration & dosage , Estazolam/pharmacokinetics , Adolescent , Adult , Area Under Curve , Biological Availability , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Female , Humans , Indonesia , Male , Tablets , Therapeutic Equivalency , Young Adult
4.
Xenobiotica ; 35(5): 455-65, 2005 May.
Article in English | MEDLINE | ID: mdl-16012077

ABSTRACT

To predict drug interactions with estazolam, the biotransformation of estazolam to its major hydoxylated metabolite, 4-hydroxyestazolam was studied in vitro using pooled human liver microsomes and individual expressed human cytochrome P450 (CYP) enzymes. Estazolam was metabolized to 4-hydroxyestazolam according to the Hill kinetic model in pooled human liver microsomes. The Km value for the 4-hydroxylation of estazolam was 24.1 microM, and the Vmax value was 52.6 pmol min(-1)mg(-1) protein. The formation of 4-hydroxyestazolam from estazolam in pooled human liver microsomes was significantly inhibited by itraconazole and erythromycin, specific CYP3A4 inhibitors, in a dose-dependent manner, with IC50 values of 1.1 and 12.8 microM, respectively. When estazolam was incubated with expressed human CYP enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), it was metabolized only by CYP3A4. In conclusion, the biotransformation of estazolam to 4-hydroxyestazolam was catalyzed by CYP3A4.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Estazolam/pharmacokinetics , Biotransformation , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Humans , Hydroxylation , Kinetics
5.
Article in English | MEDLINE | ID: mdl-12691790

ABSTRACT

The effects of the cytochrome P450 (CYP)2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam were studied in 16 healthy male volunteers. The two mutated alleles (CYP2C19*2 and CYP2C19*3) causing absent CYP2C19 activity were identified by PCR-based restriction enzyme analysis. Five subjects had no mutated allele, five had one mutated allele, and six had two mutated alleles. Seven subjects were smokers, and nine were nonsmokers. The subjects received a single oral 4-mg dose of estazolam, and blood samplings and evaluation of psychomotor function were conducted up to 72 h after dosing. There was no significant difference among the groups with no, one, and two mutated alleles for the peak plasma concentration (145.2+/-36.5 vs. 142.1+/-33.6 vs. 113.2+/-29.7 ng/ml), area under the plasma concentration-time curve (0- infinity ) (4916.0+/-1276.4 vs. 4389.6+/-736.1 vs. 4047.3+/-613.8 ng x h/ml), apparent oral clearance (0.22+/-0.05 vs. 0.25+/-0.03 vs. 0.25+/-0.03 ml/min/kg), and elimination half-life (24.4+/-4.6 vs. 29.6+/-8.5 vs. 30.7+/-3.9 h). Similarly, none of the pharmacokinetic parameters was significantly different between the nonsmoker and smoker groups. Neither the number of mutated allele nor cigarette smoking affected the psychomotor function parameters significantly. The present study suggests that neither the CYP2C19 genotype nor cigarette smoking affects the single oral dose pharmacokinetics and pharmacodynamics of estazolam.


Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Estazolam/administration & dosage , Estazolam/pharmacokinetics , Mixed Function Oxygenases/genetics , Smoking/genetics , Smoking/metabolism , Administration, Oral , Adult , Analysis of Variance , Area Under Curve , Chi-Square Distribution , Cytochrome P-450 CYP2C19 , Estazolam/blood , Genotype , Humans , Male
6.
Anal Sci ; 18(5): 525-8, 2002 May.
Article in English | MEDLINE | ID: mdl-12036118

ABSTRACT

A high-performance liquid chromatography (HPLC) assay was developed for the determination of estazolam in human plasma. Estazolam and alprazolam as an internal standard were detected by ultraviolet absorbance at 240 nm. Estazolam in plasma was extracted by a rapid and simple procedure based on cyanopropyl bonded-phase extraction. Chromatographic separation was achieved with a reversed-phase C8-5 column using a mobile phase of 0.5% potassium dihydrogenphosphate(pH 4.5)-acetonitrile (70:30, v/v). The determination of estazolam was possible in the concentration range of 1.0 - 200.0 ng/mL. The mean recovery of estazolam added to plasma was 96.1 +/- 1.5% with coefficients of variation of less than 5.5%. This method is applicable for accurately monitoring the plasma level of estazolam in healthy subjects participating in scientific research.


Subject(s)
Chromatography, High Pressure Liquid/methods , Estazolam/blood , Hypnotics and Sedatives/blood , Calibration , Estazolam/pharmacokinetics , Humans , Hypnotics and Sedatives/pharmacokinetics , Male , Reference Standards , Reference Values , Spectrophotometry, Ultraviolet
7.
Ther Drug Monit ; 24(3): 375-8, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12021628

ABSTRACT

To examine the involvement of cytochrome P450 3A4 in the metabolism of estazolam, the effect of itraconazole, a potent inhibitor of this enzyme, on the single oral dose pharmacokinetics and pharmacodynamics of estazolam was studied in a double-blind randomized crossover manner. Ten healthy male volunteers received itraconazole 100 mg/day or placebo orally for 7 days, and on the 4th day they received a single oral 4-mg dose of estazolam. Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test, Visual Analog Scale, and Stanford Sleepiness Scale were conducted up to 72 hours after estazolam dosing. There was no significant difference between the placebo and itraconazole phases for the peak plasma concentration, apparent oral clearance, and elimination half-life. Similarly, none of the psychomotor function parameters was significantly different between the two phases. The current study showed no significant effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam, suggesting that cytochrome P450 3A4 is not involved in the metabolism of estazolam to a major extent.


Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Antifungal Agents/pharmacology , Estazolam/pharmacokinetics , Itraconazole/pharmacology , Administration, Oral , Adult , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacology , Antifungal Agents/administration & dosage , Antifungal Agents/blood , Area Under Curve , Aryl Hydrocarbon Hydroxylases/metabolism , Cross-Over Studies , Cytochrome P-450 CYP3A , Double-Blind Method , Drug Administration Schedule , Drug Interactions , Estazolam/administration & dosage , Estazolam/blood , Estazolam/pharmacology , Half-Life , Humans , Itraconazole/administration & dosage , Itraconazole/blood , Male , Oxidoreductases, N-Demethylating/metabolism , Pain Measurement , Psychomotor Performance/drug effects , Reference Values
8.
Arukoru Kenkyuto Yakubutsu Ison ; 27(3): 254-65, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1524525

ABSTRACT

Effects of ethanol administration on triazolam, estazolam, diazepam, and chlordiazepoxide levels in blood and brain were investigated using rats. The brain level of triazolam was significantly increased by the concomitant oral administration of ethanol though the blood level was scarcely influenced. Estazolam levels in the blood and brain tended to be markedly raised by the ethanol administration. Diazepam levels in the blood and brain showed a tendency to be a little increased by the ethanol administration. Chlordiazepoxide levels in the blood and brain were scarcely influenced by the ethanol treatment. It was suggested that reinforcement effect of ethanol on the central nervous system depressant actions of triazolam and estazolam might appear by potentiation.


Subject(s)
Benzodiazepines/pharmacokinetics , Brain Chemistry/drug effects , Ethanol/pharmacology , Administration, Oral , Animals , Benzodiazepines/blood , Chlordiazepoxide/blood , Chlordiazepoxide/pharmacokinetics , Diazepam/blood , Diazepam/pharmacokinetics , Drug Interactions , Estazolam/blood , Estazolam/pharmacokinetics , Ethanol/administration & dosage , Gas Chromatography-Mass Spectrometry , Male , Rats , Rats, Inbred Strains , Triazolam/blood , Triazolam/pharmacokinetics
10.
Am J Med ; 88(3A): 2S-5S, 1990 Mar 02.
Article in English | MEDLINE | ID: mdl-1968715

ABSTRACT

The pharmacokinetics of estazolam were examined in 17 healthy male subjects. Plasma concentration-time profiles were compared following the oral administration of one 1-mg tablet, two 1-mg tablets, and one 2-mg tablet. No statistically significant differences were detected among the mean time of maximal plasma concentration (Tmax), maximal plasma concentration (Cmax), area under the plasma concentration-time curve from zero to 72 hours (AUC), or half-life values for the 2-mg doses. Mean Cmax was 97.7 and 98.6 ng/ml and mean Tmax was 1.9 and 1.6 hours for two 1-mg tablets and one 2-mg tablet, respectively. Proportionately decreased Cmax and AUC were observed following the 1-mg dose. Mean Cmax was 54.7 ng/ml for the 1-mg dose. Mean Tmax and elimination half-life values were similar to those observed after the 2-mg doses. The overall harmonic mean half-life was 14.4 hours.


Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Estazolam/pharmacokinetics , Administration, Oral , Adolescent , Adult , Chromatography, High Pressure Liquid , Estazolam/administration & dosage , Estazolam/blood , Half-Life , Humans , Male , Random Allocation , Tablets , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...